ArticleActa dermato-venereologica2025
Validation of the Atopic Dermatitis Control Tool (ADCT) and a Comparison with the Recap of Atopic Eczema Questionnaire (RECAP).
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of atopic dermatitis control tool (ADCT) for daily practice in a community-based dermatology clinic.Frontiers in medicine · 2026Article
- Assessing Atopic Dermatitis Control in Chinese Patients: Validation of the Chinese Version of Recap of Atopic Eczema Questionnaire (RECAP) and an Investigation into Its Interpretability.Acta dermato-venereologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Atopic Dermatitis Control Tool (ADCT) has not been validated in the Dutch population, and comparisons with the Recap of atopic eczema (RECAP) questionnaire are still lacking. This prospective study was conducted at a Dutch tertiary hospital between June 2021 and December 2022, to assess measurement properties of the Dutch ADCT in adults with atopic dermatitis (AD) and compare it with RECAP. Participants completed the ADCT, RECAP, and reference instruments including Patient's Global Assessment (PtGA), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), quality-of-life questionnaire of the EuroQol Group (EQ-5D-5L), Numeric Rating Scale (NRS) peak itch/sleep disturbance, Skindex-29, and Global Rating of Change (GRC), at baseline, 1-3 days, and 4-12 weeks. Construct validity was assessed through a priori hypotheses, whilst reliability was evaluated with standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement). Interpretability was examined using anchor-based approaches. In total, 196 adults with AD were included. Among a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. The SEMagreement was 1.15, and the ICCagreement was 0.983. The final bandings for the ADCT were established, with a binary cutoff of ≥ 6 indicating uncontrolled AD. The smallest detectable change (SDC) was 3.2, and the minimally important change (MIC) value from predictive modelling was 2.9. Furthermore, the ADCT exhibited high correlations with RECAP at all levels (most correlations being above 0.80). These results demonstrated the Dutch ADCT as a valid, reliable, and responsive tool, and have important clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.